General Information of Drug (ID: DMNGW1A)

Drug Name
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile Drug Info
Synonyms CHEMBL305128
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
14537253
TTD Drug ID
DMNGW1A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meprobamate DMHM93Y Anxiety Approved [2]
Bryostatin-1 DM1JOXY Alzheimer disease 8A20 Phase 2 [3]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
CDE-6960 DMA0DKI Inflammation 1A00-CA43.1 Terminated [6]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [8]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [8]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [8]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [9]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [10]
PMID28460551-Compound-3 DMA1FRM N. A. N. A. Patented [11]
ISIS 3521 DMZFS69 N. A. N. A. Discontinued in Phase 2 [12]
BALANOL DMDLN9E N. A. N. A. Terminated [13]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
Acteoside DM0YHKB Nephritis GB40 Terminated [14]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [10]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
CDE-6960 DMA0DKI Inflammation 1A00-CA43.1 Terminated [6]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
LY-326449 DMN53M4 Discovery agent N.A. Investigative [16]
L-serine-O-phosphate DMTJ1NH Discovery agent N.A. Investigative [17]
[2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F Discovery agent N.A. Investigative [18]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 Discovery agent N.A. Investigative [1]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [19]
RUBOXISTAURIN HYDROCHLORIDE DMQOCD8 Lymphoma 2A80-2A86 Phase 3 [20]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [10]
LY333531 DMGMC8H Solid tumour/cancer 2A00-2F9Z Phase 2 [21]
MS-553 DM7ER9J Chronic lymphocytic leukaemia 2A82.0 Phase 1 [22]
Linetastine DMF8B62 Rhinitis FA20 Discontinued in Phase 2 [23]
BALANOL DMDLN9E N. A. N. A. Terminated [13]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KAI-9803 DMELJDI Acute myocardial infarction BA41 Phase 1/2 [24]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
AD 198 DMJFY2I N. A. N. A. Terminated [25]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
LY-326449 DMN53M4 Discovery agent N.A. Investigative [16]
PROSTRATIN DM1HMJ5 Human immunodeficiency virus infection 1C62 Investigative [26]
[2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F Discovery agent N.A. Investigative [18]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 Discovery agent N.A. Investigative [1]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [27]
BALANOL DMDLN9E N. A. N. A. Terminated [13]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [28]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [8]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [8]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [8]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methyl 2-amino-4-phenylthiophene-3-carboxylate DM9BYJ0 N. A. N. A. Patented [29]
Y-9680 DMHAVYS N. A. N. A. Patented [29]
US8889696, 39 DMKXRJ4 N. A. N. A. Patented [30]
US8889672, 252-036-001 DM8B1Q4 N. A. N. A. Patented [29]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [31]
LY-326449 DMN53M4 Discovery agent N.A. Investigative [16]
[2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [1]
Protein kinase C beta (PRKCB) TTYPXQF KPCB_HUMAN Inhibitor [1]
Protein kinase C delta (PRKCD) TT9WJ8U KPCD_HUMAN Inhibitor [1]
Protein kinase C epsilon (PRKCE) TTBZ7OD KPCE_HUMAN Inhibitor [1]
Protein kinase C gamma (PRKCG) TTRFOXJ KPCG_HUMAN Inhibitor [1]
Protein kinase C theta (PRKCQ) TT8QL1J KPCT_HUMAN Inhibitor [1]
Protein kinase C zeta (PRKCZ) TTUWGRA KPCZ_HUMAN Inhibitor [1]

References

1 Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
2 Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
3 Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
4 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
5 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
7 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
8 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
9 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
10 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
11 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
12 Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
13 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
14 Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
15 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
16 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
17 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18 Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
19 The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
20 Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
21 Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
22 ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
23 Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
24 PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101.
25 Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May;1(7):469-81.
26 A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
27 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
28 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
29 Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
30 Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
31 Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.